undamentalytics Newsletter
Sign in

Regenxbio Inc. (RGNX) stock

Add to watchlist

Add holding +

NASDAQ: RGNX Nasdaq Biotechnology Next results ~November 5, 2026

Regenxbio Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Fair value per share

Under review: data-quality checks not passed.

Price vs value

Under review: data-quality checks not passed. We'll show the comparison once resolved.

Regenxbio Inc. valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders1 buying, 1 selling2 purchases and 5 sales by directors and officers, last 12 monthsInsider trades
  • Funds85 adding, 86 cuttingOf 41 active managers that changed their stake, 20 added; quarter to June 30, 2026Fund buyers and sellers

Value diary

Our note on each quarter Regenxbio files

Where Regenxbio stands after its latest 10-Q

Revenue for the twelve months to June 2026 was $174m, up 12.0% on a year earlier, against a decline of 44.0% a quarter earlier. Free-cash-flow margin fell to -143.1% from -58.2% a year earlier. Operating margin widened to -94.1% from -105.7%. The diluted share count is up 2.1% on a year earlier, which dilutes existing holders. It passes 2 of our 3 financial-health checks.

Our model value for Regenxbio is under review, so past values are not shown until it is resolved.

Source: 10-Q filed August 6, 2026 on SEC EDGAR · Financials · Valuation

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Next results ~November 5, 2026 (estimated)

Regenxbio Inc.'s trailing-twelve-month revenue grew 12.0% year on year, with a free-cash-flow margin of -143.1%.

Current signal Free cash flow diverging from earnings: TTM free cash flow fell 175.2% while net income fell 11.9%: a 163pp divergence.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Growth speeding up. The growth rate is 56.0 points higher than a quarter earlier.
  • Margins widening. Operating margin is up 11.6 points on a year ago.
  • Net cash. Cash exceeds long-term debt by $0.0bn.

Things to watch

  • Results due soon. Results are expected around 5 November; the share price can move sharply on the day.
  • Loss-making. Operating margin is -94.1%: costs exceed revenue.
  • Burning cash. Free cash flow was -143.1% of revenue over the last 12 months.
  • Heavy stock-based pay. Stock pay equals 20.1% of revenue: a real cost that cash-flow figures leave out.
  • Share dilution. Diluted shares rose 2.1% in a year.
  • Volatile shares. Over the past year the shares showed annualised volatility of 92% and a beta of 1.8 against the S&P 500.

Latest results: FY2026 Q2

Filed August 6, 2026
Earnings per share
$0.43 against an average estimate of -$0.11: beat by 499.2%
Revenue
$108m, up 405.7% on a year earlier
Share reaction
+2.1% in the first session after the results on August 6, 2026, against +0.5% for the S&P 500
Next report
November 5, 2026; average EPS estimate -$1.30

Regenxbio's figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day-0.6%
  • 1 week+8.8%
  • 1 month-3.6%
  • This year-50.3%
  • 1 year-43.9%
  • 5 years-81.0%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$174M
Operating margin
-94.1%
Net margin
-112.6%
EPS (TTM, diluted)
$-3.76

Growth

Revenue growth
+12.0%
Change in growth rate
+56.0 pts
Share count change
+2.1%

Cash

Free cash flow (TTM)
-$250M
FCF margin
-143.1%
Stock pay % of revenue
20.1%

Earnings

Last results
August 6, 2026
Next results (est.)
November 5, 2026

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Leadership
  2. Agreement
  3. Leadership
  4. Announcement
  5. Results
  6. Announcement

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Regenxbio Inc. valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: data-quality checks not passed.

The inputs used by the models below have passed source checks. Individual model values are available below and in the interactive valuator. Their differences are shown explicitly; the platform combined value and recommendation remain withheld.

Valuation models

We value Regenxbio Inc. as an operating company, with every model that fits that kind of business. Cost of equity 11.6%: the 10-year Treasury yield (4.9%) plus a beta of 1.49 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Growth cash-flow model Revenue for this year and next from analysts' consensus, then growth fading to 2.5%; the operating margin moving to profitable peers'; investment needed per dollar of growth from peers; reduced by a failure probability. For young or fast-growing companies. The starting margin is normalized to between -100% and 60%; net margin is a proxy when operating income is not tagged. Uses analysts' consensus estimates (third-party data), not our forecasts. — Does not apply: This model is withheld pending its input or assumption review.
Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. — Does not apply: This model is withheld pending its input or assumption review.
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. — Does not apply: This model is withheld pending its input or assumption review.
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: This model is withheld pending its input or assumption review.
Forward price-to-sales vs peers Next year's consensus sales per share times peers' typical forward price-to-sales; only when earnings are negative. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$12 ~$12–$45 Included, half weight
Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. — Does not apply: This model is withheld pending its input or assumption review.
Combined value Individual source-checked model scenarios are available. The platform combined value and recommendation remain withheld. — Combined value withheld. Review the individual models and their assumptions.

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Regenxbio Inc. with Biotechnology in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Valuation multiples over time Market data may be delayed

At fiscal year end 20152016201720182019202020212022202320242025Now
Share price$16.60$18.55$33.25$41.95$40.97$45.36$32.70$22.68$17.95$7.73$14.40$7.16
Market value$457m$490m$993m$1.5bn$1.5bn$1.7bn$1.4bn$979m$785m$383m$743m$374m
+ Net debt (− = net cash)−$54m−$25m−$47m−$76m−$70m−$338m−$345m−$97m−$35m−$58m−$34m−$36m
Enterprise value$403m$465m$947m$1.5bn$1.4bn$1.4bn$1.1bn$882m$751m$325m$708m$337m
Multiples
Price / sales 60.2x106.8x95.6x7.0x42.7x10.9x3.1x8.7x8.7x4.6x4.4x2.1x
Price / earnings ———15.4x——11.2x—————
Price / free cash flow ———16.8x——10.7x—————
EV / EBITDA ———15.9x——6.4x—————

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

19 /100

Weak moat

How hard Regenxbio's competitive advantage looks for rivals to wear away, judged from 10 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 0 / 20

    Net income has been a median -30.1% of total assets over 10 years.

  • Pricing power 12 / 20

    Gross margin has been a median 76.6%, moving by 15.3 percentage points (standard deviation) across 7 years.

  • Durability 10 / 20

    Operating margin has been a median -137.7%; its worst year was -872.5%.

  • Cash conversion 2 / 20

    Free cash flow was positive in 2 of 10 years, at a median -156.3% of revenue.

  • Discipline 0 / 20

    The diluted share count rose 39.1% over five years; stock-based pay has been a median 32.0% of revenue.

AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (24 before it).

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Next results: November 5, 2026, before the open. Analysts expect revenue of $16m and EPS of −$1.30 (range −$1.63 to −$0.89) for the quarter.

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current −$3.49 +7% $166m −3%
Next −$2.97 +15% $205m +24%

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is +25.1% on 90 days ago. In the last 30 days, 4 analysts raised Regenxbio Inc.'s forecast and 3 cut it.

Consensus EPS forecast Regenxbio Inc., last 90 days
−$4.00 −$3.00 −$2.00 −$1.00 $0.00 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: −$2.79 Current fiscal year, 60 days ago: −$3.43 Current fiscal year, 30 days ago: −$3.52 Current fiscal year, 7 days ago: −$3.49 Current fiscal year, Now: −$3.49 −$3.49 Next fiscal year, 90 days ago: −$2.54 Next fiscal year, 60 days ago: −$2.31 Next fiscal year, 30 days ago: −$3.00 Next fiscal year, 7 days ago: −$2.98 Next fiscal year, Now: −$2.97 −$2.97

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago −$2.79−$2.54
60 days ago −$3.43−$2.31
30 days ago −$3.52−$3.00
7 days ago −$3.49−$2.98
Now −$3.49−$2.97

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 −$0.11 $0.43 +499.2%
Mar 2026 −$1.41 −$1.72 −21.6%
Dec 2025 −$0.84 −$1.30 −54.9%
Sept 2025 −$1.30 −$1.20 +7.6%

Adjusted EPS as companies report it, against the average analyst estimate.

Analyst recommendations

12 analysts, Oct 2026
Buy1083%
Hold217%
Sell00%

Monthly trend

  1. Oct 202637212
  2. Sep 202636211
  3. Aug 202636211
  4. Jul 202646111

Counts of recommendations published by analysts covering Regenxbio Inc., by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
16.1%
of tradable shares
Days to cover
6.44
at average volume
Short interest, 1 month
+27%
to October 15, 2026
Held by institutions
65%
of shares
Held by insiders
6.5%
of shares
Employees
371
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

What moved the share price

Last 12 months −43.9%

$12.77 on October 31, 2025 to $7.16

ThenNowEffect
Revenue (last 12 months) $156m $174m +12.0%
P/S multiple 4.2x 2.1x −48.9%
Share count 51m 52m −2.0%

Biggest factor: p/s multiple. Loss-making at one end, so the split uses price/sales.

Last 3 years −53.3%

$15.33 on November 3, 2023 to $7.16

ThenNowEffect
Revenue (last 12 months) $97m $174m +79.9%
P/S multiple 6.9x 2.1x −68.7%
Share count 43m 52m −17.0%

Biggest factor: p/s multiple. Loss-making at one end, so the split uses price/sales.

The effects multiply back to the price change exactly. Results are the last 12 months as known on each date (filings assumed public 45 days after quarter end).

Return and risk by year

Calendar year 202120222023202420252026 to date
Return
RGNX−28%−31%−21%−57%+86%−50%
Industry peers (median)−36%−57%−17%−28%−5%−26%
S&P 500+29%−18%+26%+25%+18%+11%
Months that ended higher
RGNX42%33%33%33%75%18%
S&P 50075%42%67%75%75%46%
Largest fall from a high during the year
RGNX−42%−45%−48%−71%−39%−65%
S&P 500−5%−25%−10%−8%−19%−9%

Worst fall since November 3, 2015: 94% from July 10, 2018 to April 8, 2025. Getting back needed a 1447% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$5.65 – $15.98
From 52-week high
−55.2%
vs 50-day average
−9.5%
vs 200-day average
−21.6%
Volatility (1 year)
92%
Beta vs S&P 500
1.78

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
6 up, 6 down
typical move ±10.0%
After a week
8 up, 4 down
typical move ±16.0%
After a month
6 up, 6 down
typical move ±16.9%
Results releasedNext dayS&P 500 next day5 days21 days
August 6, 2026 +2.1% +0.5% +1.5% −14.9%
May 14, 2026 −43.0% −0.4% −32.8% −29.6%
March 5, 2026 −5.4% −1.9% −0.7% −3.7%
November 6, 2025 −3.4% −1.0% +0.3% +14.0%
August 7, 2025 −4.6% +0.7% +10.1% +15.2%
May 12, 2025 +8.8% +4.0% +30.2% +35.6%
March 13, 2025 +0.7% +0.7% +25.3% −11.7%
November 6, 2024 +25.4% +3.3% +19.6% +7.4%
August 1, 2024 −8.5% −3.3% −16.6% −14.2%
May 8, 2024 −7.5% +0.6% −4.3% −17.0%
February 27, 2024 +8.5% +0.1% +34.2% +20.9%
November 8, 2023 +2.3% −0.7% +16.4% +19.1%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Fundamentals

Revenue (TTM) Regenxbio Inc.
$50M $100M $150M $200M FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue (TTM), FY23 Q3: $99.4M Revenue (TTM), FY23 Q4: $90.2M Revenue (TTM), FY24 Q1: $86.7M Revenue (TTM), FY24 Q2: $89M Revenue (TTM), FY24 Q3: $84.3M Revenue (TTM), FY24 Q4: $83.3M Revenue (TTM), FY25 Q1: $156.7M Revenue (TTM), FY25 Q2: $155.8M Revenue (TTM), FY25 Q3: $161.3M Revenue (TTM), FY25 Q4: $170.4M Revenue (TTM), FY26 Q1: $87.8M Revenue (TTM), FY26 Q2: $174.5M $174.5M

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue (TTM)
FY23 Q3 $99.4M
FY23 Q4 $90.2M
FY24 Q1 $86.7M
FY24 Q2 $89M
FY24 Q3 $84.3M
FY24 Q4 $83.3M
FY25 Q1 $156.7M
FY25 Q2 $155.8M
FY25 Q3 $161.3M
FY25 Q4 $170.4M
FY26 Q1 $87.8M
FY26 Q2 $174.5M
Revenue growth, TTM YoY Regenxbio Inc.
-100% -50% 0% 50% 100% 150% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue growth, TTM YoY, FY23 Q3: -79.3% Revenue growth, TTM YoY, FY23 Q4: -19.9% Revenue growth, TTM YoY, FY24 Q1: -20.9% Revenue growth, TTM YoY, FY24 Q2: -8.2% Revenue growth, TTM YoY, FY24 Q3: -15.1% Revenue growth, TTM YoY, FY24 Q4: -7.7% Revenue growth, TTM YoY, FY25 Q1: 80.7% Revenue growth, TTM YoY, FY25 Q2: 74.9% Revenue growth, TTM YoY, FY25 Q3: 91.3% Revenue growth, TTM YoY, FY25 Q4: 104.5% Revenue growth, TTM YoY, FY26 Q1: -44.0% Revenue growth, TTM YoY, FY26 Q2: 12.0% 12.0%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue growth, TTM YoY
FY23 Q3 -79.3%
FY23 Q4 -19.9%
FY24 Q1 -20.9%
FY24 Q2 -8.2%
FY24 Q3 -15.1%
FY24 Q4 -7.7%
FY25 Q1 80.7%
FY25 Q2 74.9%
FY25 Q3 91.3%
FY25 Q4 104.5%
FY26 Q1 -44.0%
FY26 Q2 12.0%
Operating margin (TTM) Regenxbio Inc.
-400% -300% -200% -100% 0% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Operating margin (TTM), FY23 Q3: -263.6% Operating margin (TTM), FY23 Q4: -297.1% Operating margin (TTM), FY24 Q1: -306.5% Operating margin (TTM), FY24 Q2: -279.4% Operating margin (TTM), FY24 Q3: -291.6% Operating margin (TTM), FY24 Q4: -280.0% Operating margin (TTM), FY25 Q1: -100.4% Operating margin (TTM), FY25 Q2: -105.7% Operating margin (TTM), FY25 Q3: -96.0% Operating margin (TTM), FY25 Q4: -94.6% Operating margin (TTM), FY26 Q1: -292.3% Operating margin (TTM), FY26 Q2: -94.1% -94.1%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Operating margin (TTM)
FY23 Q3 -263.6%
FY23 Q4 -297.1%
FY24 Q1 -306.5%
FY24 Q2 -279.4%
FY24 Q3 -291.6%
FY24 Q4 -280.0%
FY25 Q1 -100.4%
FY25 Q2 -105.7%
FY25 Q3 -96.0%
FY25 Q4 -94.6%
FY26 Q1 -292.3%
FY26 Q2 -94.1%
FCF margin (TTM) Regenxbio Inc.
-300% -200% -100% 0% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 FCF margin (TTM), FY23 Q3: -232.8% FCF margin (TTM), FY23 Q4: -253.1% FCF margin (TTM), FY24 Q1: -229.0% FCF margin (TTM), FY24 Q2: -218.7% FCF margin (TTM), FY24 Q3: -219.1% FCF margin (TTM), FY24 Q4: -210.7% FCF margin (TTM), FY25 Q1: -55.5% FCF margin (TTM), FY25 Q2: -58.2% FCF margin (TTM), FY25 Q3: -65.9% FCF margin (TTM), FY25 Q4: -74.1% FCF margin (TTM), FY26 Q1: -269.2% FCF margin (TTM), FY26 Q2: -143.1% -143.1%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period FCF margin (TTM)
FY23 Q3 -232.8%
FY23 Q4 -253.1%
FY24 Q1 -229.0%
FY24 Q2 -218.7%
FY24 Q3 -219.1%
FY24 Q4 -210.7%
FY25 Q1 -55.5%
FY25 Q2 -58.2%
FY25 Q3 -65.9%
FY25 Q4 -74.1%
FY26 Q1 -269.2%
FY26 Q2 -143.1%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-Q. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2013 Dec 2013 2014 Dec 2014 2015 Dec 2015 2016 Dec 2016 2017 Dec 2017 2018 Dec 2018 2019 Dec 2019 2020 Dec 2020 2021 Dec 2021 2022 Dec 2022 2023 Dec 2023 2024 Dec 2024 2025 Dec 2025 LTM Jun 2026
Income
Revenue 6 6 8 5 10 219 35 155 470 113 90 83 170 174
Gross profit — — — — 9 209 27 119 419 58 53 50 — —
EBITDA −5 −4 −23 −65 −73 92 −142 −111 170 −250 −251 −217 −146 −149
Operating income −5 −4 −23 −65 −76 88 −149 −119 160 −263 −268 −233 −161 −164
Net income −5 −4 −23 −63 −73 100 −95 −111 128 −280 −263 −227 −194 −196
Diluted EPS −$0.83 −$0.61 −$0.86 −$2.38 −$2.45 $2.73 −$2.58 −$2.98 $2.91 −$6.50 −$6.02 −$4.59 −$3.76 −$3.76
Growth (year on year)
Revenue — +0.5% +24.0% −39.5% +126.5% +>999% −83.9% +338.7% +204.3% −76.0% −19.9% −7.7% +104.5% +12.0%
EBITDA — — — — — — −254.0% — — −247.4% — — — —
Operating income — — — — — — −269.1% — — −264.3% — — — —
Net income — — — — — — −194.8% — — −319.3% — — — —
Diluted EPS — — — — — — −194.5% — — −323.4% — — — —
Margins
Gross margin — — — — 83.6% 95.6% 76.6% 76.9% 89.0% 51.6% 58.8% 59.7% — —
EBITDA margin −78.5% −60.2% −303.9% <−999% −704.3% 42.1% −402.6% −71.7% 36.0% −221.8% −277.9% −260.6% −85.4% −85.3%
Operating margin −78.5% −60.2% −304.9% <−999% −730.2% 40.3% −422.9% −77.1% 34.0% −233.2% −297.1% −280.0% −94.6% −94.1%
Net margin −88.5% −65.4% −300.6% <−999% −704.0% 45.7% −268.9% −72.0% 27.2% −248.7% −292.0% −272.5% −113.8% −112.6%
Free-cash-flow margin — — −303.6% <−999% −626.9% 41.8% −339.0% −52.4% 28.6% −211.3% −253.1% −210.7% −74.1% −143.1%
Cash flow
Cash from operations −3 −2 −23 −49 −58 105 −108 −54 219 −207 −218 −173 −124 −247
Capital spending — — 1 8 7 13 12 27 84 31 10 2 2 3
Free cash flow — — −23 −57 −65 91 −119 −81 135 −238 −228 −176 −126 −250
Stock-based pay — 0 3 7 11 17 27 32 39 41 40 38 35 35
Free cash flow after stock pay — — −26 −64 −76 75 −146 −113 96 −279 −269 −214 −161 −285
Balance sheet
Cash 1 1 54 25 47 76 70 338 345 97 35 58 34 36
Total debt 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Net debt (negative = net cash) −1 −1 −54 −25 −47 −76 −70 −338 −345 −97 −35 −58 −34 −36
Diluted shares 7m 8m 28m 26m 30m 37m 37m 37m 44m 43m 44m 50m 52m 52m

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

2 of 3 checks passed · June 30, 2026
What it owns · $387m
Short-term assets $236mLonger-term assets $150m
What it owes, and who funded it · $387m
Short-term liabilities $83mLonger-term liabilities $232mShareholders' equity $72m
  • Short-term assets cover short-term liabilities $236m of assets due within a year against $83m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $236m short-term assets against $232m of longer-dated liabilities.
  • More cash than debt Cash or debt not separately reported. Not assessable.
  • Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
  • Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
  • A year's operating cash flow covers at least 20% of debt Cash flow or debt not reported. Not assessable.
  • Operating profit covers interest at least five times over Operating income of −$164m against $42m of interest.

From Regenxbio Inc.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

Diluted share count
+2.1%
year over year
R&D spending
131.3%
of revenue
Days sales outstanding
223 days
receivables vs revenue

Competitors: side by side with peers

Closest by revenue in biotechnology
Last 12 months unless stated RGNX NUVB ABUS IBRX URGN BEAM Median
Revenue, last 12 months $174m $170m $182m $166m $189m $156m $58m
Revenue growth, last 12 months 12.0% >999% >999% 192.9% 100.3% 158.9% 12.3%
Revenue growth, 3-year average 21.6% — 97.6% 554.3% 37.6% 24.9% 14.3%
Revenue growth, latest quarter 405.7% 555.6% −90.6% 93.9% 199.2% −94.2% 10.2%
Gross margin 59.7% 54.3% — 99.3% 90.8% — 82.8%
Operating margin −94.1% −81.0% 82.0% −151.9% −35.3% −242.3% −187.2%
Operating margin, 3-year average −159.7% <−999% −377.3% <−999% −86.7% −344.8% −361.6%
Net margin −112.6% −88.2% 84.2% −598.6% −51.7% −54.7% −163.5%
Cash from operations / revenue −141.4% −70.9% −13.6% −169.6% −84.2% −230.3% −162.3%
Free-cash-flow margin −143.1% −72.2% −13.6% −173.8% −84.3% −238.9% −156.7%
Free-cash-flow margin, 3-year average −140.0% <−999% −376.7% <−999% −105.5% −290.8% −306.5%
Stock pay / revenue 20.1% 20.9% 3.0% 20.7% 8.5% 52.2% 20.1%
Change in share count 2.1% 9.5% 1.9% 26.1% 4.7% 16.3% 8.1%

Median of all 185 companies we cover in biotechnology. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Where the revenue comes from

Fiscal year to December 31, 2025
Products and services
Line of business Revenue YoY
Licenses and services $156M ▲ 90.7%
Zolgensma and Itvisma Royalties $83.2M ▲ 2.1%
Zolgensma Royalties $82.5M ▲ 1.3%
Nippon Shinyaku Licenses $72.9M —
Services $14.2M ▲ 936.1%
Total Service Revenue $14.2M ▲ 936.1%
Nippon Shinyaku Services $11.8M —
Other Service Revenue $2.4M ▲ 71.9%
Itvisma Royalties $641,000 —

These categories overlap or exclude eliminations, so shares aren't shown.

From Regenxbio Inc.'s 10-K filed March 5, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Who owns it

Funds buying and selling
Reported value
$506M
Institutions reporting
162
Shares held vs prior quarter
▼ 0.8%
Positions opened / closed
24 / 34

Top buyers and sellers, Q2 2026: 85 institutions bought and 86 sold ; the biggest buyer was Marshall Wace, LLP (+1.3M shares) and the biggest seller Qube Research & Technologies Ltd (−1.3M). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Blackrock, Inc. $76.6M 6.4M 15.1% ▲ 10.6%
Redmile Group, LLC $52.3M 4.4M 10.3% 0.0%
State Street Corp $35.6M 3.0M 7.0% ▲ 8.8%
Jpmorgan Chase & Co $26.2M 2.2M 5.2% ▼ 36.4%
Vanguard Capital Management LLC $25.2M 2.1M 5.0% ▲ 5.0%
Morgan Stanley $23.4M 2.0M 4.6% ▼ 5.5%
Goldman Sachs Group Inc $17M 1.4M 3.4% ▼ 22.7%
AQR Capital Management LLC $16.5M 1.4M 3.3% ▲ 31.1%
Vanguard Portfolio Management LLC $16.2M 1.4M 3.2% ▲ 33.0%
Marshall Wace, LLP $15.4M 1.3M 3.0% New
Geode Capital Management, LLC $14.9M 1.2M 2.9% ▲ 9.1%
Integral Health Asset Management, LLC $9.6M 800K 1.9% ▼ 46.7%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Regenxbio Inc.'s complete shareholder register. Values are as reported by the filers ; 1 inconsistently scaled filing rows were excluded.

Insider trading activity

Full insider history and chart
Insider purchases History → $949,541 2 trades by 1 insider, last 12 months Insider sales History → $939,970 5 trades by 1 insider · 100% under pre-set plans
Net ▲ $9,571 net buying
Insider Date Trade Shares Price Value
Ciongoli Gregory Austin Director August 27, 2026 Buy 53,407 $9.36 $499,890
Ciongoli Gregory Austin Director August 26, 2026 Buy 49,196 $9.14 $449,651
Pakola Steve Chief Medical Officer July 2, 2026 Sell pre-set plan 2,161 $13.64 $29,476
Pakola Steve Chief Medical Officer July 1, 2026 Sell pre-set plan 36,725 $12.86 $472,284
Pakola Steve Chief Medical Officer June 29, 2026 Sell pre-set plan 19,608 $11.04 $216,472
Pakola Steve Chief Medical Officer May 11, 2026 Sell pre-set plan 15,309 $11.02 $168,705
Pakola Steve Chief Medical Officer March 10, 2026 Sell pre-set plan 5,124 $10.35 $53,033

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Trades by members of Congress

All 2 trades and filings

No trades in Regenxbio Inc. disclosed in the last 12 months; 2 earlier trades on record.

  • Peter Welch(D-VT):Sale (full), $1,001 - $15,000, traded November 8, 2019, filed November 14, 2019
  • Peter Welch(D-VT):Purchase, $1,001 - $15,000, traded October 22, 2019, filed November 14, 2019

Value ranges as filed; reports can arrive up to 45 days after a trade.

Earnings dates and SEC filings

Results announcements

Next expected around November 5, 2026 estimated from the company's past filing pattern, not announced

  • August 6, 2026
  • May 14, 2026
  • March 5, 2026
  • November 6, 2025
  • August 7, 2025
  • May 12, 2025

Recent SEC filings

Data status

When each part of this page on Regenxbio Inc. was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Regenxbio Inc. in brief

What does Regenxbio Inc. do?
Regenxbio Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.
What is Regenxbio Inc.'s stock ticker?
Regenxbio Inc. trades under the ticker RGNX on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Regenxbio Inc.'s revenue, and how fast is it growing?
Over its most recent trailing twelve months, Regenxbio Inc. reported revenue of $174M, 12.0% higher than a year earlier, according to its SEC filings.
What is Regenxbio Inc.'s free cash flow?
Regenxbio Inc.'s free-cash-flow margin is -143.1% of revenue over the trailing twelve months.
Who are Regenxbio Inc.'s largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Blackrock, Inc., Redmile Group, LLC and State Street Corp. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
What is Regenxbio Inc.'s market cap?
On November 2, 2026, Regenxbio Inc.'s market capitalisation was about $374M and net debt of -$36.5M. Market figures come from third-party market data and may be delayed.
Who are Regenxbio Inc.'s competitors?
In our Biotechnology peer group, the companies closest to Regenxbio Inc. are Nuvation Bio Inc., Arbutus Biopharma Corp, Immunitybio, Inc., Urogen Pharma Ltd. and Beam Therapeutics Inc. The side-by-side comparison below sets their revenue, margins and growth against Regenxbio Inc.'s.
Are insiders buying or selling Regenxbio Inc. stock?
Over the last 12 months, Regenxbio Inc.'s directors and officers reported 2 open-market purchases and 5 sales on Form 4. The insider trading page charts every trade.
When is Regenxbio Inc.'s next earnings date?
Around November 5, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Regenxbio Inc. announces its own schedule.